News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts
Jaguar Health's crofelemer, the only oral drug approved under FDA's Botanical Guidance, shows promising results in rare disease and cancer therapy-related diarrhea programs. Expected Q2-Q4 2025 catalysts discussed -
-
-
-
-
-
-